Arch Biopartners Arranges Non-Brokered Private Placement

Financial Post · GlobeNewswire · 2026-11-06 12:22 UTC

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has arranged a non-brokered private placement offering of 1,058,823 common shares priced at $0.85 per common share (the “Common Shares”), for gross proceeds of $900,000 CAD (the “Offering”).

The proceeds of the Offering will be used by Arch to begin onboarding clinical sites in the U.S. for the Company’s Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury, to accelerate pre-clinical studies for the Company’s IL-32 chronic kidney disease program, to market the Company to a larger financial and industry audience, and for general working capital to be used for operating expenses.

The Offering will settle on or about November 12, 2026, and is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including conditional and final approvals from the TSX Venture Exchange, as well as the satisfaction of customary closing conditions.

Read the full story at Financial Post · All coverage of this story